Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
Peer Reviewed
See detailInhibiteurs de l'enzyme de conversion de l'angiotensine ou antagonistes des récepteurs de l'angiotensine 2 en pathologie cardio-vasculaire et néphrologique : que nous dit l'Evidence Based Medicine?
Krzesinski, Jean-Marie ULiege; Montrieux, Christian ULiege; Scheen, André ULiege

in Revue Médicale de Liège (2006), 61(5-6), 414-422

Inhibitors of the renin-angiotensin system have proved their great value in secondary prevention trials for cardiovascular or renal complications. In favour of the preferred use of angiotensin receptor ... [more ▼]

Inhibitors of the renin-angiotensin system have proved their great value in secondary prevention trials for cardiovascular or renal complications. In favour of the preferred use of angiotensin receptor antagonists stand their excellent tolerance and the possible therapeutic escape seen with angiotensin converting enzyme inhibitors. For the preferential use of the latter, the arguments are the absence of a real proof of any superiority of the angiotensin receptor blockers and their higher cost. The wisdom is to initially use angiotensin converting enzyme inhibitors in secondary prevention excepted when they are not well tolerated. The large ONTARGET cardiovascular prevention trial should help solve this controversy. [less ▲]

Detailed reference viewed: 450 (4 ULiège)
Full Text
Peer Reviewed
See detailLes inhibiteurs de l'enzyme de conversion: la molécule a-t-elle de l'importance?
Rorive, Georges ULiege; Krzesinski, Jean-Marie ULiege

in Médecine et Hygiène (1991), 49

De nombreuses, peut-être de trop nombreuses molécules, dotées d'un pouvoir d'inhibition de l'enzyme de conversion ont été introduites ces dix dernières années pour le traitement de l'hypertension ... [more ▼]

De nombreuses, peut-être de trop nombreuses molécules, dotées d'un pouvoir d'inhibition de l'enzyme de conversion ont été introduites ces dix dernières années pour le traitement de l'hypertension artérielle et de l'asystolie. Les différences entre ces molécules sont peu importantes et sont fonction de leur structure moléculaire. Le captopril, seul dérivé doté d'un groupe sulfhydrile, a un effet rapide et de durée assez brève; son utilisation s'accompagne par ailleurs de certains effets secondaires propres au groupe SR. Par contre, le délai d'action des dérivés dont le ligand est un groupe carboxyle est généralement plus tardif, leur durée d'action plus longue, justifiant une prise par jour. Il reste difficile d'affirmer que le groupe SR confère des propriétés cardioprotectrices plus importantes que celles dont jouissent les autres molécules de cette classe thérapeutique. De la même manière, à ce stade, les différences démontrées concernant la diffusion tissulaire des inhibiteurs de l'enzyme de conversion n'ont pas pu être illustrées par des observations cliniques. [less ▲]

Detailed reference viewed: 16 (0 ULiège)
Full Text
See detailLes inhibiteurs de l'enzyme de conversion: leur place dans le traitement de l'hypertension artérielle
Rorive, Georges ULiege; Krzesinski, Jean-Marie ULiege; Carlier, P. G.

in Traité de Médecine Générale (1987)

Detailed reference viewed: 10 (0 ULiège)
Full Text
Peer Reviewed
See detailInhibiteurs de la monoamine oxydase et anesthésie
Blom-Peters, L.; Larbuisson, Robert ULiege; Lamy, Maurice ULiege

in Revue Médicale de Liège (1988), XLIII(2), 51-56

Detailed reference viewed: 30 (2 ULiège)
Full Text
Peer Reviewed
See detailInhibiteurs de la pompe à protons et risque d'insuffisance rénale
PAQUOT, Francois ULiege; Krzesinski, Jean-Marie ULiege

in Revue Médicale Suisse (2017)

Regarded as safe and effective for management of upper peptic ulcer disease due to gastric acid secretion, the proton pump inhibitors are among the most commonly prescribed drugs. Their use, however, is ... [more ▼]

Regarded as safe and effective for management of upper peptic ulcer disease due to gastric acid secretion, the proton pump inhibitors are among the most commonly prescribed drugs. Their use, however, is not without concerns. Acute kidney injury, mainly due to acute interstitial nephritis, could happen 1.5 to 2 times more frequently when using these drugs. Moreover, a risk for chronic kidney disease has also be noted with proton pump inhibitor use (1.15 to 1.8 increased risk), although biases may exist due to confounding factors related to the observational nature of the studies. So, caution is required before available results from good prospective randomized studies are available. Renal function should be checked when using these medications and timely cessation should be advised when there is no more clear indication for use. [less ▲]

Detailed reference viewed: 63 (5 ULiège)
Full Text
See detailLes inhibiteurs de la PSCK9: une innovation majeure dans le traitement des dyslipidémies ?
PAQUOT, Nicolas ULiege

in ABD- le supplément du médecin (2014), 57(6), 6-7

Detailed reference viewed: 67 (8 ULiège)
Full Text
Peer Reviewed
See detailInhibiteurs des calcifications cardiovasculaires.
Liabeuf, Sophie; DELANAYE, Pierre ULiege; Cavalier, Etienne ULiege et al

in Annales de Biologie Clinique (2015), 73(3), 315-22

Vascular calcification is a marker of cardiovascular risk increase. Age and specific disease such as diabetes or chronic kidney disease are important factors for calcification genesis. Vascular ... [more ▼]

Vascular calcification is a marker of cardiovascular risk increase. Age and specific disease such as diabetes or chronic kidney disease are important factors for calcification genesis. Vascular calcification process is a complex phenomenon, involving several activators and inhibitors factors. Indeed, recent works related to in vitro and in vivo experimental studies have led to a better understanding of calcification process and identification of molecules able to modulate this system. This revue will summarize some of these molecules with a particular interest of those with therapeutic relevance. We will present: i) calcium sensing receptor and its modulation by cinacalcet; ii) pyrophosphate supplementation; iii) fetuin A and overall propensity serum test for calcification and finally; iv) matrix-Gla-protein and the use of vitamin K to prevent vascular calcification progression. [less ▲]

Detailed reference viewed: 20 (0 ULiège)
Full Text
Peer Reviewed
See detailInhibiteurs du cotransporteur du glucose SGLT rénal pour traiter le diabète de type 2
SCHEEN, André ULiege; RADERMECKER, Régis ULiege; ERNEST, Philippe ULiege et al

in Revue Médicale Suisse (2011), 7(306), 1621-1629

Detailed reference viewed: 51 (12 ULiège)
Full Text
See detailLes inhibiteurs du cotransporteur du glucose SGLT rénal: une nouvelle classe thérapeutique dans le diabète de type 2
Sepulchre, Edith; RADERMECKER, Régis ULiege

in Journal de Cardiologie = Tijdschrift voor Cardiologie (2013), 25(8), 429-434

Detailed reference viewed: 110 (2 ULiège)
Full Text
Peer Reviewed
See detailInhibiteurs du cotransporteur du glucose SGLT2 renal pour traiter le diabete de type 2.
SCHEEN, André ULiege; Radermecker, Régis ULiege; Ernest, P. et al

in Revue medicale suisse (2011), 7(306), 1621-41626-9

Kidney plays a role in glucose homeostasis, not only by its capacity to produce glucose through local gluconeogenesis, but also, and even more important in presence of diabetes, by its capacity to excrete ... [more ▼]

Kidney plays a role in glucose homeostasis, not only by its capacity to produce glucose through local gluconeogenesis, but also, and even more important in presence of diabetes, by its capacity to excrete glucose in urine when hyperglycaemia exceeds tubular reabsorption threshold. Such reabsorption depends on sodium-glucose cotransporters-2 (SGLT2), which can be blocked by selective inhibitors. These pharmacological agents augment glucosuria and reduce hyperglycaemia independently of insulin. Some have already proven their efficacy to improve glucose control, in monotherapy or in combination, while promoting weight loss and without inducing hypoglycaemia. Dapagliflozin should be the first medication of this new pharmacological class to be commercialized for the management of type 2 diabetes. [less ▲]

Detailed reference viewed: 67 (3 ULiège)
Peer Reviewed
See detailInhibiteurs potentiels de proteases à sérine apparentés aux antibiotiques β-lactamiques
Pirotte, Bernard ULiege; Vilain, A.-C.; Vergely, I. et al

in Regard sur la Biochimie (1991), 6, 91

Detailed reference viewed: 10 (0 ULiège)
Full Text
Peer Reviewed
See detailInhibiting Effect of Ammonia on Citric Acid-Induced Cough in Pigs: A Possible Involvement of Substance P
Moreaux, B.; Nemmar, A.; Beerens, Dominique ULiege et al

in Pharmacology & Toxicology (2000), 87(6), 279-285

The effect of ammonia on the cough response to citric acid and on substance P release from C-fibers involved in this reflex was assessed. For a period from one to four days, piglets were exposed, in an ... [more ▼]

The effect of ammonia on the cough response to citric acid and on substance P release from C-fibers involved in this reflex was assessed. For a period from one to four days, piglets were exposed, in an inhalation chamber, to ammonia at a concentration of 15 or 30 ppm. During exposure, cough induction tests were done every two days. Recovery of the cough reflex after ammonia exposure was also determined. In a separate group of piglets exposed for 2 days to 30 ppm ammonia, substance P content was determined in bronchial and tracheal lavage fluids and in the tracheal and bronchial mucosa. Ammonia (30 ppm) was found to inhibit coughing significantly (the cough frequency was reduced by 64%) after a two-day exposure. In animals exposed for 4 days to this ammonia concentration, the recovery ranged from 3 to 7 days (mean: 5 days). The same ammonia concentration also caused the substance P content to increase significantly in bronchoalveolar lavage fluid (to 432% of its initial value) and tracheal lavage fluid (to 149%) and to decrease significantly in the tracheal mucosa (-58%), however the content in bronchial mucosa was not significantly affected (-43%). Exposure to 15 ppm ammonia had no effect on the frequency of citric acid-induced coughing. In conclusion, ammonia inhibits citric acid-induced coughing in pigs at concentrations that can be detected in piggeries. This inhibitory effect may be related to substance-P depletion in C-fiber endings [less ▲]

Detailed reference viewed: 19 (1 ULiège)
Full Text
Peer Reviewed
See detailInhibiting or Antagonizing Glucagon: A Progress in Diabetes Care ?
LEFEBVRE, Pierre ULiege; Paquot, Nicolas ULiege; Scheen, André ULiege

in Diabetes, obesity & metabolism (2015)

Absolute or relative hyperglucagonemia has been recognized for years in all experimental or clinical forms of diabetes. It has been suggested that excess secretion of glucagon by the islet alpha-cells is ... [more ▼]

Absolute or relative hyperglucagonemia has been recognized for years in all experimental or clinical forms of diabetes. It has been suggested that excess secretion of glucagon by the islet alpha-cells is a direct consequence of intra-islet insulin secretory defects. Recent studies have demonstrated that knock-out of the glucagon receptor or administration of a monoclonal specific glucagon receptor antibody make insulin deficient type 1 diabetic rodents thrive without insulin. These observations suggest that glucagon plays an essential role in the pathophysiology of diabetes and that targeting the alpha-cell and glucagon are innovative approaches in the management of diabetes. Despite active research and identification of promising compounds, no one selective glucagon antagonist is presently used in the treatment of diabetes. Interestingly, besides insulin, several drugs used today in the management of diabetes appear to exert their effects in part by inhibiting glucagon secretion (GLP-1 receptor agonists, DPP-4 inhibitors, alpha glucosidase inhibitors and, maybe, sulfonylureas) or glucagon action (metformin). The potential risks associated with total glucagon suppression include alpha-cell hyperplasia, increased mass of the pancreas, increased susceptibility to hepatosteatosis and hepatocellular injury and increased risk of hypoglycaemia and should be considered in the search and development of new compounds reducing glucagon receptor signalling. In conclusion, more than 40 years after its initial description, the hyperglucagonemia of diabetes can no longer be ignored or minimized and its correction represents an attractive way for improving diabetes management. [less ▲]

Detailed reference viewed: 29 (4 ULiège)
Full Text
See detailL’INHIBITION DE LA MÉTHYLTRANSFÉRASE EZH2 DU COMPLEXE RÉPRESSEUR POLYCOMB FAVORISE LA RÉPONSE ANTI-TUMORALE DES MACROPHAGES M2 DIRIGÉE CONTRE LES CELLULES DU MÉSOTHÉLIOME PLEURAL MALIN
Hamaïdia, Malik ULiege

Doctoral thesis (2017)

Context: Malignant pleural mesothelioma (MPM) is an aggressive neoplasm affecting mesothelial cells from the pleura, pericardium and peritoneum. The disease is closely associated to asbestos exposure ... [more ▼]

Context: Malignant pleural mesothelioma (MPM) is an aggressive neoplasm affecting mesothelial cells from the pleura, pericardium and peritoneum. The disease is closely associated to asbestos exposure. Despite of rules to reduce workplace exposure to asbestos, incidence of mesothelioma is predicted to increase until 2020. Since MPM is resistant to conventional cancer therapies such as surgery, irradiation and chemotherapy, development of new options is urgently needed. In my project, I investigate the ability of immunotherapy to improve patients' outcome. My hypothesis postulates that tumor cells are tightly controlled by the immune system. In fact, clinical evidence indicates that tumor infiltration by tumor associated macrophages (TAMs) correlates with poor prognosis in malignant mesothelioma (MM). By attenuating the immune response, TAMs indeed promote survival of MM cells. TAMs share properties with alternative macrophages (M2) and are activated by anti-inflammatory (e.g. IL-10) or Th2-associated (i.e. IL-4, IL-13) cytokines. In contrast, classical (M1) macrophages are stimulated by interferon (IFN)-γ and microbial components (e.g. LPS). Aim: We hypothesized that macrophage activation is mediated by a transcriptional program tightly regulated by epigenetic modifications. We focused on the Polycomb Repressive Complex 2 (PRC2) EZH2 lysine methyltransferase responsible for trimethylation of histone H3 at lysine 27 (H3K27me3). Results: Our data show that inhibition of EZH2 reduces phagocytic activity by M2-polarised macrophages. Moreover, the cytotoxicity of supernatants conditioned by M2-macrophages is increased in presence of the EZH2 inhibitor. Finally, inhibition of EZH2 enhances the tumoricidal potential of M2 macrophages towards MM cells. We further demonstrate that macrophage killing activity requires superoxide radicals (O2.-) and peroxynitrites (ONOO-) derivatives produced by the NADPH oxidase system. Conclusion: EzH2 inhibition implements the tumoricidal potential of macrophages and may therefore improve the efficacy of immunotherapy of MM patients. [less ▲]

Detailed reference viewed: 45 (17 ULiège)
Full Text
Peer Reviewed
See detailInhibition de la sclérostine par le romosozumab chez des femmes ménopausées ayant une DMO basse : résultats de l'étude de phase 2
Brown, JP; McClung, MR; Grauer, A et al

in Revue du Rhumatisme (2013), 80(S1), 73

Detailed reference viewed: 27 (1 ULiège)